CROMS NIDCR Clinical Monitoring

Slides:



Advertisements
Similar presentations
1 US Investigator Meeting DIAS-4, Chicago, July 2011 Good Clinical Practice (GCP) for Investigators and the Research Team.
Advertisements

1 US Investigator Meeting DIAS-4, Chicago, July 2011 Informed Consent.
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Essential Documentation GCP Training Seminar 12th October 2011
Maintenance, Management and Monitoring of Investigational Supply
Tips to a Successful Monitoring Visit
Chicken Soup for the Busy Coordinator
Checking & Corrective Action
GCP for Investigators Tina Lidén Mascher, Kvalitetsregister, forskning och industrisamarbeten.
Managing Regulatory Documents Electronically
Quality Management within the Clinical Research Process
CROMS C linical Research Operations and Management Support Rho, Inc., Federal Division NIDCR National Institute of Dental and Craniofacial Research National.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
A Blueprint For Clinical Research: Standard Operating Procedures
Good Clinical Practice in Research
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Developed by Klinikos; Roy Fraser (2012) Investigator Study File
John Naim, PhD Director Clinical Trials Research Unit
Stanley Estime, MSCI December 9, 2014 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
Internal Auditing in Research: The QA Process Research Education Series February 14, 2011 Sarah Dutkevitch, RN, OCN, Clinical Research Nurse Specialist.
Monitoring and Special Considerations for Multi-Center Trials
M ODULE H I NTERIM M ONITORING V ISIT Denise Thwing 21 Apr Version: Final 21-Apr-2010.
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
MODULE I Close-Out Visit/Monitoring Reports Jane Fendl April 24, Versions: Final 24-Apr-2010.
STUDY CLOSE OUT KEMRI-Wellcome Trust Research Programme Version: 4-Nov-2008.
Common Audit Findings UTHSC Institutional Review Board (IRB)
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Tough Love: Understanding the Purpose and Processes of Quality Assurance.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
Research Studies GOTCHA’S By Sally Duffy. Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified.
1 Denise K. Thwing, MAS, RN, CCRA March 31, 2010 Version: Final 31-Mar-2010.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
AUDIT REQUIREMENTS, FINDINGS & BASICS RESEARCH COMPLIANCE.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Human Subjects Research Office of Responsible Research Practices Human Subjects Research Vanessa Hill, MSHS, CCRC Senior Quality Improvement Specialist.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Site Monitoring Shirley Frederiksen Donna Harsh.
Stanley Estime, MSCI October 19, 2015 Record Keeping: What is Regulatory Documentation and how should it be maintained? Tel:
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
Checking and Corrective Action EPA Regions 9 & 10 and The Federal Network for Sustainability 2005.
Sponsor Visits and Monitoring
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Lifespan GOOD CLINICAL PRACTICE Record Management GCP May 2005.
Research Documentation Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic Compliance, Corporate Compliance.
Good Clinical Practices and Best Research Practices at MU Health Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic.
Office of Human Research (OHR) Quality Improvement Program Patrick Herbison Heather Krupinski.
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
IRB BASICS BETTY WILSON, MS, CIP. CONCEPTS SUBMISSION APPROVAL RECRUITING WORKING WITH PRINCIPAL INVESTIGATOR (PI) /SPONSOR POLICIES DEVIATIONS RECORD.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
GCP (GOOD CLINICAL PRACTISE)
Slide 1 Standard Operating Procedures. Slide 2 Goal To review the standard operating procedures Creating the informed consent document Obtaining informed.
Responsibilities of Sponsor, Investigator and Monitor
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Good Clinical Practice (GCP) and Monitoring Practices
Remote Site Initiation Visits
The Role and Responsibilities of the Clinical Research Coordinator
Stephanie Oppenheimer, MS SUCCESS Center Erica Ellington, CRA, CHRC
Responsibilities of Sponsor, Investigator and Monitor
IRB reporting updates.
Reportable Events & Other IRB Updates February 2017
Alyssa Speier, MS, CIP November 13, 2013
Reasons for Auditing There are many reasons for auditing. Some examples of these reasons might be: Requested by the IRB Committee Requested by an IRB.
Regulatory Binder: Maintaining Essential Study Documentation
Elements of an Organized Regulatory Binder
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Quality Control SOP 3.12 Release Date: 08/10/2015.
CONDUCTING THE TRIAL AT
Good clinical practice
Presentation transcript:

CROMS NIDCR Clinical Monitoring Clinical Research Operations and Management Support Rho, Inc., Federal Division NIDCR National Institute of Dental and Craniofacial Research National Institutes of Health 2012-06-07

Clinical Monitoring The monitor/CRA will review study documents to confirm adherence to: Good Clinical Practice (GCP) Data integrity Informed consent Study protocol All other applicable regulations 2012-06-07

On-Site Visits 3 types of visits will be conducted by the CRA: Interim monitoring For-cause monitoring Close-out 2012-06-07

Visit Scheduling Rho CRA schedules the visit with the study team. Visit confirmation letter and agenda will be provided to the site approximately 2 weeks before visit. Visit schedule and level of monitoring is outlined in the approved Clinical Monitoring Plan (CMP). Timing and frequency of visits are based on several factors, including: level of risk, intervention, and enrollment 2012-06-07

Visit Requirements During on-site visits, the CRA will need access to the following: Work space Investigator site file (including access to ISF documents maintained electronically, if applicable) Research records (paper and electronic) All original, signed consent forms 2012-06-07

Interim Monitoring Visit Activities Consent form review Original documents Percentage to be reviewed is outlined in CMP Documentation of consent process in chart Chart review/source verification The number of charts and percentage of data in each chart to be reviewed is addressed in the CMP Investigator site file review Serious Adverse Events, Unanticipated Problems Protocol Deviations 2012-06-07

Consent Form Review Obtained prior to initiation of study procedures Process documented in source Date and time Version reviewed Study personnel conducting the discussion(s) Topics discussed with subject Adequate time for review of consent and questions Subject received copy of consent Valid signatures and dates Correct version signed, including updates 2012-06-07

Source Documentation and Data Collection Form Review The CRA will verify: Accurate, complete, and current source documentation is being maintained Subject eligibility Completion of protocol-specified procedures Proper documentation and reporting of UPs/SAEs in the source and data collection forms Accuracy of data recorded on data collection forms 2012-06-07

Investigator Site File Review Verify and review all required essential documents Verify all documents are current and expired documents are replaced, with maintenance of previous versions Review Delegation of Responsibilities Log to ensure it is current and includes all site staff with signatures and appropriate study responsibilities Review Training Logs Sign Monitoring Visit Log for each day of the visit 2012-06-07

Unanticipated Problems/Serious Adverse Events The CRA will: Follow-up on previously reported UPs/SAEs Verify all newly reported events against source documentation Identify unreported events recorded in source documentation Confirm events reported to IRB and as outlined in the protocol 2012-06-07

Protocol Deviations The CRA will: Identify potential deviations for discussion with study team Verify that deviations are documented in source Verify deviations were reported to the IRB Address deviations with site personnel and establish plans to prevent future occurrence 2012-06-07

For-Cause Visit Activities May include: Activities generally conducted during a regularly scheduled monitoring visit Discussion and review of site operations and study management Training/re-training, as appropriate 2012-06-07

Close-Out Visit Activities Will include: Final consent form review Verification of required essential documents Completion of data review and source verification Confirmation of UP/SAE reporting in data collection forms and IRB Confirm that all lab samples have been shipped and appropriately stored Close-out with IRB Confirm location of study record storage and ensure PI is aware of applicable record retention policies. 2012-06-07

Monitoring Visit Follow-Up Activities The CRA will: Review visit findings and help develop an action plan if needed Answer questions Depending on the study, send a visit report and action item tracker, or a follow-up letter and action item tracker Work with the study team to schedule a teleconference approximately 4-6 weeks after completion of visit to follow-up on outstanding action items 2012-06-07

Contact Information Lauren McGurk, Senior CRA Ph: 919-595-6858 Email: lauren_mcgurk@rhoworld.com 2012-06-07